Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Return on Sales (2020 - 2026)

Rani Therapeutics Holdings' Return on Sales history spans 6 years, with the latest figure at 0.05% for Q1 2026.

  • On a quarterly basis, Return on Sales rose 69.0% to 0.05% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.11%, a 34.0% increase, with the full-year FY2025 number at 0.25%, up 30.0% from a year prior.
  • Return on Sales came in at 0.05% for Q1 2026, up from 0.06% in the prior quarter.
  • The five-year high for Return on Sales was 0.05% in Q1 2026, with the low at 0.74% in Q1 2025.
  • Historically, Return on Sales has averaged 0.31% across 4 years, with a median of 0.37% in 2022.
  • Biggest five-year swings in Return on Sales: plummeted -34bps in 2022 and later soared 69bps in 2026.
  • Year by year, Return on Sales stood at 0.37% in 2022, then skyrocketed by 58bps to 0.15% in 2024, then skyrocketed by 62bps to 0.06% in 2025, then increased by 19bps to 0.05% in 2026.
  • Business Quant data shows Return on Sales for RANI at 0.05% in Q1 2026, 0.06% in Q4 2025, and 0.4% in Q3 2025.